Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. (2020)
Attributed to:
Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41375-020-0750-z
PubMed Identifier: 32157174
Publication URI: http://europepmc.org/abstract/MED/32157174
Type: Journal Article/Review
Volume: 34
Parent Publication: Leukemia
Issue: 11
ISSN: 0887-6924